Clinical Trial: A Study to Learn About a Medicine (Called Elranatamab) in People With Relapsed Refractory Multiple Myeloma

U.S., Nov. 10 -- ClinicalTrials.gov registry received information related to the study (NCT07927023) titled 'A Study to Learn About a Medicine (Called Elranatamab) in People With Relapsed Refractory Multiple Myeloma' on Nov. 03.

Brief Summary: This study is to understand how well elranatamab (PF-06863135) may be used for relapsed refractory multiple myeloma (RRMM). Sometimes MM might improve at first, but then gets resistant to the treatment and starts growing again (known as relapsed refractory). This study medicine will be compared with standard-of-care (SOC) therapies used in real-world clinical practice. For people receiving elranatamab, we will use data from the phase 3 clinical trial (MagnetisMM-5). We will also use data from a real-...